載入中
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
前收盤價
US$154.49
+US$1.97 · +1.29%
盤中時間採用ET。市場資料可能有所延遲。
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
日內區間
目前US$154.49
52週區間
目前US$154.49
盤中時間採用ET。市場資料可能有所延遲。
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
日內區間
目前US$154.49
52週區間
目前US$154.49
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 4537.7萬 USD | 2993.9萬 USD | 2484.4萬 USD | 886.9萬 USD | 741.9萬 USD |
| 銷售、一般及管理費用 | 3883.1萬 USD | 1005.7萬 USD | 682.4萬 USD | 395.2萬 USD | 237.8萬 USD |
| 營業費用 | 8420.8萬 USD | 3999.6萬 USD | 3166.8萬 USD | 1282.1萬 USD | 979.7萬 USD |
| 利息收入 | — | 373.7萬 USD | 7.4萬 USD | 2.3萬 USD | 5000 USD |
| 利息支出 | — | 2萬 USD | 2.5萬 USD | 1.6萬 USD | — |
| 折舊和攤銷 | 46.4萬 USD | 44.9萬 USD | 39.9萬 USD | 19.8萬 USD | 3萬 USD |
| 營業利益 | −8420.8萬 USD | −3999.6萬 USD | −3166.8萬 USD | −1282.1萬 USD | −979.7萬 USD |
| 淨利 | −7761.1萬 USD | −3614.4萬 USD | −3163.2萬 USD | −1264.8萬 USD | −966.6萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$245.83
上漲空間 59.12%報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM459.41萬0.03%175.23億 USD0.07%US$52.21+1.32%
ICBC CSOP S&P New China Sectors ETF3167.HK77.32萬0.22%3.65億 HKD1.13%HK$56.04+0.11%
ActivePassive International Equity ETFAPIE64.98萬0.06%11.41億 USD0.45%US$38.56+0.65%
Fidelity Nasdaq Composite Index ETFONEQ57.15萬0.01%109.4億 USD0.21%US$107.81+0.63%
State Street SPDR S&P China ETFGXC48.68萬0.11%4.46億 USD0.59%US$86.47+1.87%
Virtus Biotech Clinical Trials ETFBBC35.03萬0.85%4099.65萬 USD0.65%US$44.1456+2.08%
Even Herd Long Short ETFEHLS19.78萬0.34%5883.5萬 USD2.62%US$25.4482+0.28%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM6.6萬0.01%6.94億 USD0.89%US$57.70+0.92%State Street SPDR Portfolio Emerging Markets ETFSPEMICBC CSOP S&P New China Sectors ETF3167.HKActivePassive International Equity ETFAPIEFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P China ETFGXCVirtus Biotech Clinical Trials ETFBBCEven Herd Long Short ETFEHLSMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
